The global tumor necrosis factor receptor superfamily member 18 market is expected to grow at a CAGR of XX% during the forecast period. The growth of this market can be attributed to the increasing prevalence of cancer, which is one of the major factors driving this market. The other factors that are driving this market are increasing research and development activities in the field, technological advancements in drug discovery and development, and growing awareness about cancer among people. The global tumor necrosis factor receptor superfamily member 18 market by type includes AM228, BM986156, FP154, GW323 and INCAG1876. Among these types, AM228 segment accounted for XX% share in 2018. This segment is expected to maintain its dominance throughout the forecast period owing to its high efficacy against melanoma cells as well as its low toxicity profile when compared with other drugs used for treatment of melanoma such as BRAF inhibitors or MEK inhibitors. The global tumor necrosis factor receptor superfamily member 18 market by application includes melanoma (XX%), no small cell lung cancer (XX%), gastric cancer (XX%), blood cancer (XX%). Among these applications, melanoma segment accounted for XX% share in 2018 due to increased incidence rates across all age groups worldwide coupled with lack of effective treatments available for advanced stages of disease progression.
Some Of The Growth Factors Of This Market:
- Tumor Necrosis Factor Receptor Superfamily Member 18 is a protein that is involved in the immune system and inflammation.
- Tumor Necrosis Factor Receptor Superfamily Member 18 has been shown to be an important factor in the development of cancer, autoimmune diseases, and other inflammatory conditions.
- The market for Tumor Necrosis Factor Receptor Superfamily Member 18 is expected to grow due to its involvement in the immune system and inflammation which are both growing markets themselves.
- The market for Tumor Necrosis Factor Receptor Superfamily Member 18 will also grow due to its involvement with cancer, autoimmune diseases, and other inflammatory conditions which are all growing markets as well.
- The market for Tumor Necrosis Factor Receptor Superfamily Member 18 will also grow due to its use as a therapeutic target for drug discovery programs which are also growing markets.
Industry Growth Insights published a new data on “Tumor Necrosis Factor Receptor Superfamily Member 18 Market”. The research report is titled “Tumor Necrosis Factor Receptor Superfamily Member 18 Market research by Types (AMG-228, BMS-986156, FPA-154, GWN-323, INCAGN-1876, Others), By Applications (Melanoma, Non-Small Cell Lung Cancer, Gastric Cancer, Blood Cancer, Others), By Players/Companies Ablynx NV, Amgen Inc, Apogenix GmbH, Bristol-Myers Squibb Company, Five Prime Therapeutics Inc, Incyte Corp, MedImmune LLC, Merck & Co Inc, Novartis AG, OncoMed Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tumor Necrosis Factor Receptor Superfamily Member 18 Market Research Report
By Type
AMG-228, BMS-986156, FPA-154, GWN-323, INCAGN-1876, Others
By Application
Melanoma, Non-Small Cell Lung Cancer, Gastric Cancer, Blood Cancer, Others
By Companies
Ablynx NV, Amgen Inc, Apogenix GmbH, Bristol-Myers Squibb Company, Five Prime Therapeutics Inc, Incyte Corp, MedImmune LLC, Merck & Co Inc, Novartis AG, OncoMed Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Report Segments:
The global Tumor Necrosis Factor Receptor Superfamily Member 18 market is segmented on the basis of:
Types
AMG-228, BMS-986156, FPA-154, GWN-323, INCAGN-1876, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Melanoma, Non-Small Cell Lung Cancer, Gastric Cancer, Blood Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ablynx NV
- Amgen Inc
- Apogenix GmbH
- Bristol-Myers Squibb Company
- Five Prime Therapeutics Inc
- Incyte Corp
- MedImmune LLC
- Merck & Co Inc
- Novartis AG
- OncoMed Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
Highlights of The Tumor Necrosis Factor Receptor Superfamily Member 18 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AMG-228
- BMS-986156
- FPA-154
- GWN-323
- INCAGN-1876
- Others
- By Application:
- Melanoma
- Non-Small Cell Lung Cancer
- Gastric Cancer
- Blood Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tumor Necrosis Factor Receptor Superfamily Member 18 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
TNFRSF18 is a protein that belongs to the tumor necrosis factor receptor superfamily. TNFRSF18 is specifically responsible for mediating the inflammatory response in cells.
Some of the major companies in the tumor necrosis factor receptor superfamily member 18 market are Ablynx NV, Amgen Inc, Apogenix GmbH, Bristol-Myers Squibb Company, Five Prime Therapeutics Inc, Incyte Corp, MedImmune LLC, Merck & Co Inc, Novartis AG, OncoMed Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tumor Necrosis Factor Receptor Superfamily Member 18 Market - Supply Chain
4.5. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Forecast
4.5.1. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Absolute $ Opportunity
5. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Type
5.3.1. AMG-228
5.3.2. BMS-986156
5.3.3. FPA-154
5.3.4. GWN-323
5.3.5. INCAGN-1876
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Application
6.3.1. Melanoma
6.3.2. Non-Small Cell Lung Cancer
6.3.3. Gastric Cancer
6.3.4. Blood Cancer
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Demand Share Forecast, 2019-2026
9. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Application
9.4.1. Melanoma
9.4.2. Non-Small Cell Lung Cancer
9.4.3. Gastric Cancer
9.4.4. Blood Cancer
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Type
9.7.1. AMG-228
9.7.2. BMS-986156
9.7.3. FPA-154
9.7.4. GWN-323
9.7.5. INCAGN-1876
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tumor Necrosis Factor Receptor Superfamily Member 18 Demand Share Forecast, 2019-2026
10. Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Application
10.4.1. Melanoma
10.4.2. Non-Small Cell Lung Cancer
10.4.3. Gastric Cancer
10.4.4. Blood Cancer
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Type
10.7.1. AMG-228
10.7.2. BMS-986156
10.7.3. FPA-154
10.7.4. GWN-323
10.7.5. INCAGN-1876
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tumor Necrosis Factor Receptor Superfamily Member 18 Demand Share Forecast, 2019-2026
11. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Application
11.4.1. Melanoma
11.4.2. Non-Small Cell Lung Cancer
11.4.3. Gastric Cancer
11.4.4. Blood Cancer
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Aplication
11.7. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Type
11.7.1. AMG-228
11.7.2. BMS-986156
11.7.3. FPA-154
11.7.4. GWN-323
11.7.5. INCAGN-1876
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Demand Share, 2019-2026
12. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Application
12.4.1. Melanoma
12.4.2. Non-Small Cell Lung Cancer
12.4.3. Gastric Cancer
12.4.4. Blood Cancer
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Type
12.7.1. AMG-228
12.7.2. BMS-986156
12.7.3. FPA-154
12.7.4. GWN-323
12.7.5. INCAGN-1876
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 18 Demand Share, 2019-2026
13. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Application
13.4.1. Melanoma
13.4.2. Non-Small Cell Lung Cancer
13.4.3. Gastric Cancer
13.4.4. Blood Cancer
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size and Volume Forecast by Type
13.7.1. AMG-228
13.7.2. BMS-986156
13.7.3. FPA-154
13.7.4. GWN-323
13.7.5. INCAGN-1876
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 18 Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market: Market Share Analysis
14.2. Tumor Necrosis Factor Receptor Superfamily Member 18 Distributors and Customers
14.3. Tumor Necrosis Factor Receptor Superfamily Member 18 Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Ablynx NV
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Amgen Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Apogenix GmbH
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb Company
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Five Prime Therapeutics Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Incyte Corp
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. MedImmune LLC
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck & Co Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis AG
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. OncoMed Pharmaceuticals Inc
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Regeneron Pharmaceuticals Inc
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
&